大红袍茶降血糖作用研究

[目的]探讨大红袍茶的降血糖作用。[方法]取50只小鼠以200 mg/kg剂量、间日2次腹腔注射四氧嘧啶制造高血糖模型,4 d后得到24只血糖高于9.00 mmol/L的高血糖模型小鼠。将高血糖小鼠按相似血糖水平分为对照组和试验组,血糖值分别为（15.11±6.47）和（14.77±5.40）mmol/L,组间无显著差异（P〉0.05）。对照组饲喂基础饲料和凉开水,试验组在基础饲料中添加3.0%的大红袍茶,饮0.5%的大红袍茶汤。饲养7 d后再次测定血糖值,研究其变化。[结果]对照组小鼠血糖值为（12.23±5.11）mmol/L,无显著变化（P〉0.05）;试验组小鼠血糖值下降到（7.93±1.88）mmol/L,降低了46.3%,变化极显著（P〈0.001）。[结论]大红袍茶对高血糖小鼠有极显著的降糖作用。     

A review on the mechanisms involved in hyperglycemia induced by organophosphorus pesticides

Organophosphorus (OP) compounds are cholinesterase-inhibiting chemicals used as pesticide. Exposures to OPs cause a significant number of poisonings and deaths each year. One of the reported adverse effects in human exposure to OPs is hyperglycemia. Animal studies have also shown altered glucose homeostasis following acute or chronic exposures to OPs. The objective of this paper is to provide a brief review of the mechanisms involved in the OP-induced glucose homeostasis alteration. To reach this objective, a search of the literature using Medline/Index Medicus, Scopus, and Chemical Abstract were performed, most of relevant citations were studied and summarized. To better understand the nature of glucose homeostasis, the principles of glucose production, metabolism, and its hormonal control have been discussed. Collection of theses studies support the conclusion that hyperglycemia is the outcome of acute or chronic exposure to OPs. OPs can influence body glucose homeostasis by several mechanisms including physiological stress, oxidative stress, inhibition of paraoxonase, nitrosative stress, pancreatitis, inhibition of cholinesterase, stimulation of adrenal gland, and disturbance in metabolism of liver tryptophan.     

林下参总皂苷对高血糖大鼠的影响

目的观察林下参总皂苷(TGGUF)不同剂量组对高血糖大鼠血糖、体重、进食量、饮水量的影响。方法将正常Wistar大鼠腹腔注射0.054g/kg链脲霉素(STZ),造高血糖模型,并随机分为:模型组、消渴丸组、TGGUF高剂量组(0.40g/kg)、TGGUF中剂量组(0.20g/kg)和TGGUF低剂量组(0.10g/kg)。每日灌胃给药1次,每天记录各组大鼠的进食量和饮水量,连续给药4周,每周测空腹血糖、称体重各1次。结果TGGUF高剂量组可使高血糖大鼠血糖水平下降,抑制体重下降,进食量和饮水量减少,与模型组比较差异显著(P<0.05);TGGUF中剂量组可使高血糖大鼠血糖下降、饮水量减少,与模型组比较差异显著(P<0.05)。结论林下参总皂苷可使高血糖大鼠的血糖水平下降、体重增长、进食量和饮水量减少。     

Blood glucose concentrations in critically ill neonatal foals

Reasons for Performing Study: Critical illness is associated with hyperglycemia in humans, and a greater degree and duration of hyperglycemia is associated with nonsurvival. Hypoglycemia is also seen in critically ill humans, and is associated with nonsurvival. This might also be true in the critically ill foal.
Objectives: To investigate the association of blood glucose concentrations with survival, sepsis, and the systemic inflammatory response syndrome (SIRS).
Methods: Blood glucose concentrations at admission (515 foals) and 24 hours (159 foals), 36 hours (95), 48 hours (82), and 60 hours (45) after admission were analyzed. Logistic regression analyses were performed to investigate the association of glucose concentrations with survival, sepsis, a positive blood culture, or SIRS.
Results: 29.1% of foals had blood glucose concentrations within the reference range (76–131 mg/dL) at admission, 36.5% were hyperglycemic, and 34.4% were hypoglycaemic. Foals that did not survive to hospital discharge had lower mean blood glucose concentrations at admission, as well as higher maximum and lower minimum blood glucose concentrations in the 1st 24 hours of hospitalization, and higher blood glucose at 24 and 36 hours. Foals with blood glucose concentrations <2.8 mmol/L (50 mg/dL) or >10 mmol/L (180 mg/dL) at admission were less likely to survive. Hypoglycemia at admission was associated with sepsis, a positive blood culture, and SIRS.
Conclusions and Potential Relevance: Derangements of blood glucose concentration are common in critically ill foals. Controlling blood glucose concentrations may therefore be beneficial in the critically ill neonatal foal, and this warrants further investigation.     

Blood glucose in horses with acute abdominal disease

BACKGROUND: Hyperglycemia in critically ill humans is associated with increased glucose production and insulin resistance and is associated with death. This might also be true in horses presenting with acute abdominal disease. HYPOTHESIS: Throughout hospitalization, hyperglycemia will be common in adult horses presenting with acute abdominal disease. Hyperglycemia will be associated with a worse prognosis for survival to hospital discharge. ANIMALS: Two hundred sixty-nine adult horses with acute abdominal disease. METHODS: Observational retrospective study. Records were reviewed for 269 horses that had glucose data analysed and recorded at the time of hospital admission: 154 horses had a first sample after admission; 110 horses at 24 hours after admission; 74 horses at 36 hours after admission; and 49 horses at 48 hours after admission. Logistic regression analyses were performed to investigate the association of glucose concentrations with survival, in addition to the association of glucose concentrations with surgical, small intestinal, strangulating lesions, and lesions requiring a resection. RESULTS: Of 269 horses presenting with acute abdominal disease, 50.2% had blood glucose concentrations greater than the reference range (75.6-131.4 mg/dL); 0.4%, below the reference range; and 49.4%, within the reference range at admission. Of 269 horses, 2.3% had blood glucose concentrations below the reference range at some point during the first 48 hours of hospitalization, all of which had strangulating intestinal lesions. Horses that did not survive to hospital discharge had a higher mean blood glucose concentration at admission; at the first sample after admission; at 24, 36, and 48 hours after admission; and higher maximum and minimum blood glucose concentrations in the first 24 hours after admission. CONCLUSIONS AND CLINICAL IMPORTANCE: Derangements of blood glucose concentration are common in horses with acute abdominal disease. Hyperglycemia is much more common than hypoglycemia in these animals. Hyperglycemia in the first 48 hours of hospitalization is associated with a worse prognosis for survival to hospital discharge.     

茳芒对糖尿病大鼠降糖效应的研究

观察不同剂量茳芒水提物对试验性糖尿病大鼠血糖的影响。将70只Wistar大鼠随机分为7组,即正常对照组、模型组、优降糖组、消渴丸组、茳芒水提物剂量组（大、中、小）,每组10只。模型组及各给药组大鼠一次性腹腔注射链脲霉素（0.054 g/kg）造成高血糖动物模型。每日计量灌胃给药1次,连续给药4周。于给药第4周末,麻醉各组受试动物,腹主动脉取血,分别测血常规、血液生化指标。给药4周后,茳芒水提物大、中剂量组可使Wistar大鼠高血糖动物模型血糖水平下降,与模型组比较,具有明显统计学意义的差异（P〈0.01,P〈0.05）,与消渴丸、优降糖具有相似的作用。茳芒水提物可使高血糖大鼠的血糖水平下降,具有降低高血糖大鼠血糖值的作用。     

Protection by cAMP and cGMP phosphodiesterase inhibitors of diazinon-induced hyperglycemia and oxidative/nitrosative stress in rat Langerhans islets cells: Molecular evidence for involvement of non-cholinergic mechanisms

The objective of this study was to study the effects of acute administration of diazinon alone or in combination with two phosphodiesterase (PDE) inhibitors with selectivity to cAMP and cGMP (theophylline and sildenafil, respectively) on oxidative/nitrosative stress biomarkers, including nitric oxide (NO), lipid peroxides (TBARS), total antioxidant power (TAP), and concentration of tumor necrosis factor (TNF-α) in isolated Langerhans islets, plasma glucose and insulin levels, and the activity of plasma cholinesterase (ChE). Examination by different doses of diazinon (15, 30, and 60 mg/kg) in single administration lead us to choose diazinon (30 mg/kg) in combination therapies. Theophylline and sildenafil were used at doses of 25 and 5 mg/kg, respectively. In all diazinon-treated groups, plasma ChE activity and plasma insulin level were significantly decreased and plasma glucose concentration and Langerhans islets TNF-α, TBARS, and NO levels were significantly increased in comparison to controls. The TAP did not change in comparison to control. In combination therapy, both theophylline and sildenafil restored diazinon-induced changes in plasma glucose concentration, Langerhans islets TNF-α, NO, and TBARS concentrations but Langerhans islets TAP, plasma insulin, and ChE levels. It is concluded that diazinon stimulates oxidative/nitrosative stress in Langerhans islets that results in hyperglycemia due to insufficiency of insulin. Altered glucagons/insulin ratio, activated hepatic glucose production/release, and insulin resistance are possible mechanisms. The protective effects of cAMP and cGMP PDE inhibitors in restoration of diazinon-induced oxidative/nitrosative stress and hyperglycemia stress back to their antioxidant potentials that seem to be independent of ChE inhibition.     

Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats

Metformin is an oral antidiabetic drug that improves control of glycemia primarily by inhibiting hepatic gluconeogenesis and glycogenolysis. This study evaluated the usefulness of metformin for the treatment of diabetes mellitus in cats. The study consisted of 3 phases. Phase I was a dose-finding study performed in healthy cats that were randomly administered varying doses of metformin to determine the approximate dose that would yield plasma concentrations known to be effective in humans. Phase 2 was a 3-week safety study performed in healthy cats to determine if cats could tolerate the daily oral dose and administration protocol identified during phase 1. Phase 3 was a clinical trial evaluating the clinical response of diabetic cats to oral metformin treatment. Five cats with newly diagnosed, naturally acquired diabetes mellitus were enrolled in phase 3. Plasma metformin concentrations in the therapeutic range of 0.5-2 microg/mL were achieved with doses of 50 mg/cat PO q12h without dramatic drug accumulation. Intermittent lethargy, inappetence, vomiting, and weight loss were identified, and the results of the CBC, serum biochemical analysis, plasma lactate concentration, and urinalysis remained within the reference range during phase 2 of the study. During phase 3, control of glycemia was achieved in 1 of 5 diabetic cats after 8 weeks of metformin treatment; 3 cats failed to respond to metformin, and treatment with insulin was initiated after 7-8 weeks of metformin treatment; 1 cat died unexpectedly 11 days after starting metformin treatment. The cause of death was not determined. The serum insulin concentration was within or greater than the reference range in the responder diabetic cat and was undetectable or at the low end of the reference range in the nonresponder diabetic cats. The results of this study suggest that metformin is beneficial only in those diabetic cats with detectable concentrations of insulin at the time metformin treatment is initiated.     

Intensive Intravenous Infusion of Insulin in Diabetic Cats

Background

Remission occurs in 10–50% of cats with diabetes mellitus (DM). It is assumed that intensive treatment improves β‐cell function and increases remission rates.

Hypothesis

Initial intravenous infusion of insulin that achieves tight glycemic control decreases subsequent insulin requirements and increases remission rate in diabetic cats.

Animals

Thirty cats with newly diagnosed DM.

Methods

Prospective study. Cats were randomly assigned to one of 2 groups. Cats in group 1 (n = 15) received intravenous infusion of insulin with the goal of maintaining blood glucose concentrations at 90–180 mg/dL, for 6 days. Cats in group 2 (n = 15) received subcutaneous injections of insulin glargine (cats ≤4 kg: 0.5–1.0 IU, q12h; >4 kg 1.5–2.0 IU, q12h), for 6 days. Thereafter, all cats were treated with subcutaneous injections of insulin glargine and followed up for 6 months. Cats were considered in remission when euglycemia occurred for ≥4 weeks without the administration of insulin. Nonparametric tests were used for statistical analysis.

Results

In groups 1 and 2, remission was achieved in 10/15 and in 7/14 cats (P = .46), and good metabolic control was achieved in 3/5 and in 1/7 cats (P = .22), respectively. Overall, good metabolic control or remission occurred in 13/15 cats of group 1 and in 8/14 cats of group 2. In group 1, the median insulin dosage given during the 6‐month follow‐up was significantly lower than in group 2 (group 1: 0.32 IU/kg/day, group 2: 0.51 IU/kg/day; P = .013).

Conclusions and Clinical Importance

Initial intravenous infusion of insulin for tight glycemic control in cats with DM decreases insulin requirements during the subsequent 6 months.